Overview

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

Status:
Not yet recruiting
Trial end date:
2033-12-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the effects of chemoradiation and Tislelizumab on Esophageal/EGJ Cancer before and after surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Zhonglin Hao
Collaborators:
BeiGene
University of Kentucky